Tdap vaccine

Phase 2Vaccine

Sanofi

Tdap vaccine is one of 42 biologic programs targeting Atopic Dermatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic DermatitisActive, not recruiting

DiphtheriaActive, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

DiphtheriaPhase 1

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Immunotherapy

Bristol-Myers Squibb

Phase 3

1 2

GR1802

GGenrix (Shanghai) Biopharmaceutical Co., Ltd.

Phase 3

1 3

Broncho-Vaxom

OOM Pharma SA

Phase 3

1 4

EBGLYSS

Eli Lilly

Preclinical

23 5

Cibinqo

Pfizer

Preclinical

11 6

OPA-15406

Otsuka

Phase 3

7 7

Product 0405

FFougera Pharmaceuticals Inc.

Phase 3

3 8

Prograf

VVeloxis Pharmaceuticals

Preclinical

18 9

Adtralza

Rituxan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Not yet recruiting

Diphtheria

NCT07492303

Clinical

Trials by Indication[1]

Atopic Dermatitis2 trials

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

Completed· LEO Pharma logo

LEO Pharma·Phase 2·NCT03562377·215 enrolled

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

Completed· Sanofi logo

Sanofi·Phase 2·NCT06015308·224 enrolled

Diphtheria1 trial

A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)

Not yet recruiting·CChangchun BCHT Biotechnology Co.·Phase 1·NCT07492303·96 enrolled

Immune Response1 trial

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents

Completed· Novartis logo

Novartis·Phase 3·NCT00518180·1,620 enrolled

Pregnant Women1 trial

GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age

Not yet recruiting·MMinervax ApS·Phase 2/3·NCT06494475·564 enrolled

Antibody Response1 trial

Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women

Completed·MMahidol University·Phase 1·NCT03498300·129 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Tdap vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tdap vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tdap vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: Sanofi

Tdap vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Atopic Dermatitis2 trials

Diphtheria1 trial

Immune Response1 trial

Pregnant Women1 trial

Antibody Response1 trial

References

Drug Info

Quick Facts

Related News